Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Completed · Phase 4

Conditions studied: Multiple Myeloma

In brief

This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.

Key facts

Study ID

NCT00622505

Run by

Novartis Pharmaceuticals

People needed

121

Starts

2007-11-07

Expected to finish

2012-04-03

Last updated by the study team

2021-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of multiple myeloma
• Have been on zoledronic acid or pamidronate for 1-2 years and therapy must have been initiated for osteolytic lesion, bone fracture, spinal compression, or osteopenia due to multiple myeloma
• Stable renal function

You may not qualify if…

• Known sensitivity to bisphosphonates
• Receiving investigational drugs considered not safe for co-administration or have a significant effect on bone turnover
• Current active dental problems
• Had bone marrow transplant or blood stem cell transplant within 2 months before study entry or planned transplant within 2 months following enrollment
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• TriValley Cancer Research and Treatment Center — Casa Grande, Arizona, United States
• Wilshire Oncology Medical Group — La Verne, California, United States
• Cedars Sinai Medical Center Outpatient Cancer Ctr. (4) — Los Angeles, California, United States
• Palo Alto Medical Foundation Hematology/Oncology — Mountain View, California, United States
• Oncology Care Medical Associates — San Gabriel, California, United States
• Santa Clara Valley Health & Hospital System — San Jose, California, United States
• University of Colorado U of Colorado Cancer Center — Aurora, Colorado, United States
• Hematology Oncology PC — Stamford, Connecticut, United States
• Washington Hospital Center — Washington D.C., District of Columbia, United States
• Palm Beach Institute of Hematology Oncology — Boynton Beach, Florida, United States
• Innovative Medical Research of South Florida Innovative Med Research — Miami Shores, Florida, United States
• Cancer Centers of Florida PA Cancer Centers of Central FL — Ocoee, Florida, United States
• Integrated Community Oncology Network Florida Oncology Associates — Orange Park, Florida, United States
• Cleveland Clinic Florida — Weston, Florida, United States
• Loyola University Medical Center /Cardinal Bernardin Cancer Loyola Univ Med Ctr — Maywood, Illinois, United States
• University of Maryland Greenebaum Cancer Center — Baltimore, Maryland, United States
• Center for Cancer & Blood Disorders — Bethesda, Maryland, United States
• Oncology - Hematology Associates, PA Oncology Hematology Assoc — Clinton, Maryland, United States
• Dana Farber Cancer Institute Clinical Research Coordinator — Boston, Massachusetts, United States
• Boston VA Healthcare Boston VA — Boston, Massachusetts, United States
• Berkshire Hematology Oncology — Pittsfield, Massachusetts, United States
• N MS Hematology & Oncology — Tupelo, Mississippi, United States
• Hematology & Oncology Consultants, PC Hematology & Oncology — Omaha, Nebraska, United States
• Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2) — Somerset, New Jersey, United States
• Cooper Cancer Center — Voorhees Township, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.